{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269479","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.050268+00:00","generated_at":"2026-05-16T23:45:10.373390+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"medium","headline":"Intellia reports patient death in nex-z trial; awaits FDA clinical hold; lonvo-z on track","bullets":["Patient who had Grade 4 liver transaminase elevations after nex-z dose in MAGNITUDE Phase 3 trial died; FDA clinical hold letter pending.","Phase 3 HAELO trial of lonvo-z for hereditary angioedema completed enrollment; topline data expected mid-2026.","Cash, equivalents and marketable securities ~$670M as of Sept 30, 2025; company expects to fund ops into mid-2027.","Longer-term Phase 1 clinical data for nex-z in ATTR-CM to be presented Nov 10 at AHA 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269479","json":"https://secwatch.observer/filing/0001193125-25-269479.json","markdown":"https://secwatch.observer/filing/0001193125-25-269479.md","text":"https://secwatch.observer/filing/0001193125-25-269479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525269479/0001193125-25-269479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525269479/d53244d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:45:10.373390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}